Julia Furtner

TL;DR: This study establishes an open resource for dissecting DNA methylation heterogeneity in a genetically diverse and heterogeneous cancer, and demonstrates the feasibility of integrating epigenomics, radiology, and digital pathology for a national cohort, thereby leveraging existing samples and data collected as part of routine clinical practice.

TL;DR: Distinct invasion patterns of brain metastases into the brain parenchyma are not specific for primary tumor types, seem to be influenced by expression of αv integrin complexes, and may help to guide clinical decision-making.

TL;DR: Strong 5-ALA fluorescence is a reliable and immediately available intraoperative marker of representative tumor tissue of malignant gliomas and intracranial lymphomas in stereotactic biopsies and may in future reduce costs for operating room and neuropathology and may decrease procedure-related morbidity.

TL;DR: The TUXEDO-1 trial as discussed by the authors showed that trastuzumab deruxtecan showed a high intracranial response rate in patients with active brain metastases from HER2-positive breast cancer and should be considered as a treatment option in this setting.

TL;DR: A new, simplified scorecard is proposed that will require validation using a similar approach as pursued here and the main challenges are to define measurable versus nonmeasurable lesions and measures of change that allow assessment of response.